#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Follicular lymphoma stage II Hereditary ataxia Malignant fibrous histiocytoma Arterial tortuosity syndrome Biliary neoplasm Mantle cell lymphoma stage IV Neoplasm malignant Pseudomyxoma peritonei Acute graft versus host disease in liver Mitochondrial myopathy Neuromyelitis optica spectrum disorder Hepatitis B Deafness neurosensory Type IIa hyperlipidaemia Behcet's syndrome More trials…

    Learn about Rare Diseases

    Medulloblastoma – Trials in Disease CADASIL Idiopathic pulmonary fibrosis – Treatment Progressive multifocal leukoencephalopathy Netherton’s syndrome – Diagnostics Cystic fibrosis Amyotrophic lateral sclerosis – Diagnostics Choroid melanoma – Life with Disease Vascular malformation – Diagnostics Mantle cell lymphoma refractory – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Casirivimab Oxacillin [11C]Az14193391 Vedolizumab Bi 690517 Chlorpromazine Hydrochloride Fosinopril Sodium Sodium Ascorbate Digitoxin ICEF15 Enfortumab Vedotin Riociguat ZOLPIDEM TARTRATE Sodium Sulfate Anhydrous Rgx-202 Indacaterol Maleate Bms-986315 Etoricoxib LY4170156 Taletrectinib More therapies…

    Learn about Your Condition

    SAPHO syndrome Somatic symptom disorder Fibrosarcoma Cardiac disorder Prostate cancer Corneal dystrophy End stage renal disease Procedural anxiety Metabolic disorder Uterine leiomyoma Colour blindness Psychotic behaviour Sciatica Herpes zoster Oral herpes More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Non-small cell lung cancer

  • Study of DCC-3116 with Sotorasib, Binimetinib, and Trametinib for Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Dcc-3116
    • Sotorasib
    France Germany Italy Spain

  • Study of Boserolimab, MK-0482, and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer Resistant to PD-(L)1 Therapy

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Boserolimab
    • Mk-0482
    • Mk-4830
    Hungary Italy Poland Spain

  • Study Comparing SB27 and Pembrolizumab for Patients with Metastatic Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Carboplatin
    • Pembrolizumab
    • Pemetrexed
    Germany Romania Spain

  • Study on Lorlatinib for Patients with ALK-Positive or ROS1-Positive Non-Small Cell Lung Cancer Continuing from Previous Studies

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Lorlatinib
    France Spain

  • Study on Re-Challenging Advanced Lung Cancer with Cemiplimab After Initial Treatment with Ipilimumab and Radiotherapy

    Not recruiting

    4 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Cemiplimab
    • Ipilimumab
    The Netherlands

  • Study of BGB-A425, LBL-007, and Tislelizumab for Patients with Advanced Head and Neck Cancer, Lung Cancer, or Kidney Cancer

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    • Renal cell carcinoma
    • Squamous cell carcinoma of head and neck
    Investigated Drugs:
    • Lbl-007
    • Surzebiclimab
    • Tislelizumab
    France Italy Poland Spain
Previous Page
1 … 47 48 49 50 51 … 54
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!